CompletedPhase 1NCT00003046
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Studying Adenocarcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Renato Lenzi, MDM.D. Anderson Cancer Center
- Intervention
- Recombinant Interleukin-12(biological)
- Enrollment
- 29 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1997 – 2001
Study locations (1)
- University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003046 on ClinicalTrials.govOther trials for Adenocarcinoma of the anal canal
Additional recruiting or active studies for the same condition.